Lucas de Oliveira Cia

Lucas de Oliveira Cia

Auto-generated profile, based on publicly available information

Lucas de Oliveira Cia

Graduate Program of Psychiatry and Behavioral Sciences, Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Applied Thermal Engineering
Verified
Journal Article
Closed access
JLJustin Lawrence Lapp
Justin Lawrence Lapp
MLMatthias Lange
Matthias Lange
RRRené Rieping
René Rieping
LOLamark de Oliveira
Lamark de Oliveira
MRMartin Roeb
Martin Roeb
CSChristian Sattler
Christian Sattler

1 April 2019 in International Journal of Hydrogen Energy
Verified
Journal Article
Closed access
CAChristos Agrafiotis
Christos Agrafiotis
DTDennis Thomey
Dennis Thomey
LOLamark de Oliveira
Lamark de Oliveira
CHChristoph Happich
Christoph Happich
MRMartin Roeb
Martin Roeb
DJDariusz Janus
Dariusz Janus

30 January 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
MCMarina Ribeiro Barreto da Costa
Marina Ribeiro Barreto da Costa
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
ÉBÉrica Bonganhi de Bem
Érica Bonganhi de Bem
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration–approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance. Given this, exploring pharmacological alternatives for more effective management of DB associated with ASD is essential. Clozapine, noted for its unique antiaggressive effects in schizophrenia and in various treatment-resistant neuropsychiatric disorders, independent from its antipsychotic efficacy, remains underexplored in youths with ASD facing severe and persistent DB. Objective: This study aimed to evaluate the efficacy, tolerability, and safety of clozapine for treatment-resistant DB in youths with ASD. Methods: This is a prospective, single-center, noncontrolled, open-label trial. After a cross-titration phase, 31 patients with ASD aged 10-17 years and with treatment-resistant DB received a flexible dosage regimen of clozapine (up to 600 mg/day) for 12 weeks. Standardized instruments were applied before, during, and after the treatment, and rigorous clinical monitoring was performed weekly. The primary outcome was assessed using the Irritability Subscale of the Aberrant Behavior Checklist. Other efficacy measures include the Clinical Global Impression Severity and Improvement, the Swanson, Nolan, and Pelham questionnaire-IV, the Childhood Autism Rating Scale, and the Vineland Adaptive Behavior Scale. Safety and tolerability measures comprised adverse events, vital signs, electrocardiography, laboratory tests, physical measurements, and extrapyramidal symptoms with the Simpsons-Angus Scale. Statistical analysis will include chi-square tests with Monte Carlo simulation for categorical variables, paired t tests or Wilcoxon tests for continuous variables, and multivariate linear mixed models to evaluate the primary outcome, adjusting for confounders. Results: Recruitment commenced in February 2023. Data collection was concluded by April 2024, with analysis ongoing. This article presents the protocol of the initially planned study to provide a detailed methodological description. The results of this trial will be published in a future paper. Conclusions: The urgent need for effective pharmacological therapies in mitigating treatment-resistant DB in pediatric patients with ASD underscores the importance of this research. Our study represents the first open-label trial to explore the anti-aggressive effects of clozapine in this specific demographic, marking a pioneering step in clinical investigation. Adopting a pragmatic approach, this trial protocol aims to mirror real-world clinical settings, thereby enhancing the applicability and relevance of our findings. The preliminary nature of future results from this research has the potential to pave the way for more robust studies and emphasize the need for continued innovation in ASD treatment. Trial Registration: Brazilian Clinical Trials Registry RBR-54j3726; https://ensaiosclinicos.gov.br/rg/RBR-54j3726 International Registered Report Identifier (IRRID): DERR1-10.2196/58031

14 October 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
LCLucas de Oliveira Cia
Lucas de Oliveira Cia
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
OBOlivia Sorato Bezerra
Olivia Sorato Bezerra
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet in children and adolescents it remains off-label and underused, constrained by safety concerns and scarce pediatric-specific evidence. Its benefits may extend beyond any single diagnostic category to severe, treatment-resistant dimensions of psychopathology that recur across diagnoses. This review traces clozapine’s history in youth, synthesizes the current evidence, and organizes it by domains of treatment resistance: psychosis, aggression, affective symptoms, suicidality and self-directed harm, and catatonia, with sections on real-world outcomes, clinical management, and safety. Randomized controlled data are confined to treatment-resistant early-onset schizophrenia and to one small trial in conduct disorder, with the first prospective open-label trial now available in autistic youth. Elsewhere the evidence is observational and of lower certainty, although convergent for aggression, suicidality, mood, and catatonia. The strongest transdiagnostic evidence is register-based and within-individual, drawn from cohorts aged 16 years and older, and spans psychotic and affective disorders; the pediatric gap concerns study design as well as sample size. Because pharmacovigilance data show that mortality is not concentrated in the hematological domain, safe use requires surveillance beyond blood counts, therapeutic drug monitoring, and safeguards over drug supply when suicide risk is present. Viewing clozapine as a treatment option defined by symptom severity and refractoriness may support rational use in severely ill youth, but the proposal remains preliminary: a conceptual framework that requires prospective, dimensionally designed pediatric studies. Clozapine’s potential transdiagnostic anti-suicidal effect merits priority investigation, given that suicide is a leading cause of death in adolescence.

3 March 2024 in JMIR Preprints
Verified
Preprint
Open access
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
MCMarina Ribeiro Barreto da Costa
Marina Ribeiro Barreto da Costa
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
ÉBÉrica Bonganhi de Bem
Érica Bonganhi de Bem
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
BACKGROUND Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration–approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance. Given this, exploring pharmacological alternatives for more effective management of DB associated with ASD is essential. Clozapine, noted for its unique antiaggressive effects in schizophrenia and in various treatment-resistant neuropsychiatric disorders, independent from its antipsychotic efficacy, remains underexplored in youths with ASD facing severe and persistent DB. OBJECTIVE This study aimed to evaluate the efficacy, tolerability, and safety of clozapine for treatment-resistant DB in youths with ASD. METHODS This is a prospective, single-center, noncontrolled, open-label trial. After a cross-titration phase, 31 patients with ASD aged 10-17 years and with treatment-resistant DB received a flexible dosage regimen of clozapine (up to 600 mg/day) for 12 weeks. Standardized instruments were applied before, during, and after the treatment, and rigorous clinical monitoring was performed weekly. The primary outcome was assessed using the Irritability Subscale of the Aberrant Behavior Checklist. Other efficacy measures include the Clinical Global Impression Severity and Improvement, the Swanson, Nolan, and Pelham questionnaire-IV, the Childhood Autism Rating Scale, and the Vineland Adaptive Behavior Scale. Safety and tolerability measures comprised adverse events, vital signs, electrocardiography, laboratory tests, physical measurements, and extrapyramidal symptoms with the Simpsons-Angus Scale. Statistical analysis will include chi-square tests with Monte Carlo simulation for categorical variables, paired t tests or Wilcoxon tests for continuous variables, and multivariate linear mixed models to evaluate the primary outcome, adjusting for confounders. RESULTS Recruitment commenced in February 2023. Data collection was concluded by April 2024, with analysis ongoing. This article presents the protocol of the initially planned study to provide a detailed methodological description. The results of this trial will be published in a future paper. CONCLUSIONS The urgent need for effective pharmacological therapies in mitigating treatment-resistant DB in pediatric patients with ASD underscores the importance of this research. Our study represents the first open-label trial to explore the anti-aggressive effects of clozapine in this specific demographic, marking a pioneering step in clinical investigation. Adopting a pragmatic approach, this trial protocol aims to mirror real-world clinical settings, thereby enhancing the applicability and relevance of our findings. The preliminary nature of future results from this research has the potential to pave the way for more robust studies and emphasize the need for continued innovation in ASD treatment. CLINICALTRIAL Brazilian Clinical Trials Registry RBR-54j3726; https://ensaiosclinicos.gov.br/rg/RBR-54j3726 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/58031